Diclofenac / misoprostol Pregnancy and Breastfeeding Warnings
Diclofenac / misoprostol is also known as: Arthrotec
Diclofenac / misoprostol Pregnancy Warnings
FDA pregnancy category: X Use of diclofenac-misoprostol is contraindicated. Adequate methods of contraception and time periods to observe should be encouraged.
Diclofenac-misoprostol is contraindicated for use in pregnant women. Misoprostol can cause abortion, premature birth, or birth defects when administered to a pregnant woman. Misoprostol may produce uterine contractions, uterine bleeding, and expulsion of the products of conception. Misoprostol has been used to ripen the cervix, to induce labor, and to treat postpartum hemorrhage, outside of its approved indication. A major adverse effect of these uses is hyperstimulation of the uterus. Uterine rupture, amniotic fluid embolism, severe genital bleeding, shock, fetal bradycardia, and fetal and maternal death have been reported. Higher doses of misoprostol may increase the risk of complications from uterine hyperstimulation. Abortions caused by misoprostol may be incomplete. If a woman is or becomes pregnant while taking this drug, the drug should be discontinued and the patient apprised of the potential hazard to the fetus. Cases of amniotic fluid embolism, which resulted in maternal and fetal death, have been reported with use of misoprostol during pregnancy. Severe vaginal bleeding, retained placenta, shock, fetal bradycardia, and pelvic pain have also been reported. These women were administered misoprostol vaginally and/or orally over a range of doses. Additionally, because of the known effects of nonsteroidal anti-inflammatory drugs including the diclofenac component, on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided. Diclofenac-misoprostol should only be used in a woman of childbearing potential, who requires NSAID therapy and is at high risk for the development of gastric ulcers, if pregnancy has been ruled out by a negative serum pregnancy test within 2 weeks of starting misoprostol, if she is capable of complying with effective methods of birth control and if she has been apprised of the risk should she become pregnant. Both written and oral warnings should be provided. In addition, the patient should be instructed that she must never share this drug with other individuals. Therapy should begin on the second or third day of the next normal menstrual cycle. FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Diclofenac / misoprostol Breastfeeding Warnings
Caution should be exercised when diclofenac-misoprostol is administered to a nursing woman. Excreted into human milk: Yes (diclofenac and misoprostol) Excreted into animal milk: Unknown The effects in the nursing infant are unknown.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.